PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$42.38 USD
-1.65 (-3.75%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $42.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.38 USD
-1.65 (-3.75%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $42.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9%
by Zacks Equity Research
The shares of PTC Therapeutics (PTCT) rose nearly 13% yesterday.
Catabasis' DMD Candidate Slows Disease Progression, Stock Up
by Zacks Equity Research
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
PTC Therapeutics, Inc. (PTCT) in Focus: Stock Moves 14.6% Higher
by Zacks Equity Research
PTC Therapeutics, Inc. (PTCT) saw its shares rise nearly 15% on the day.
Here's Why Sarepta Stock is Up More Than 60% So Far in 2017
by Zacks Equity Research
Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.
Implied Volatility Surging for PTC Therapeutics (PTCT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to PTC Therapeutics (PTCT) stock based on the movements in the options market lately.
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
by Zacks Equity Research
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.
Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy
by Zacks Equity Research
Zacks.com featured highlights: PTC Therapeutics, Catalyst Biosciences, U.S. Silica Holdings, DXC Technology and Patterson-UTI Energy
5 Stocks with Earnings Acceleration to Buy Now
by Tirthankar Chakraborty
Earnings acceleration should be viewed as a key metric for share price outperformance
Is the Options Market Predicting a Spike in PTC Therapeutics (PTCT) Stock?
by Zacks Equity Research
Investors in PTC Therapeutics, Inc. (PTCT) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in PTC Therapeutics (PTCT) Stock?
by Zacks Equity Research
Investors in PTC Therapeutics, Inc. (PTCT) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in PTC Therapeutics Stock?
by Zacks Equity Research
Investors in PTC Therapeutics, Inc. (PTCT) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in PTC Therapeutics (PTCT) Stock?
by Zacks Equity Research
Investors in PTC Therapeutics, Inc. (PTCT) need to pay close attention to the stock based on moves in the options market lately.